BR112013022801A2 - combinações de terapia para malignidades hematológicas - Google Patents
combinações de terapia para malignidades hematológicasInfo
- Publication number
- BR112013022801A2 BR112013022801A2 BR112013022801A BR112013022801A BR112013022801A2 BR 112013022801 A2 BR112013022801 A2 BR 112013022801A2 BR 112013022801 A BR112013022801 A BR 112013022801A BR 112013022801 A BR112013022801 A BR 112013022801A BR 112013022801 A2 BR112013022801 A2 BR 112013022801A2
- Authority
- BR
- Brazil
- Prior art keywords
- hematologic malignancies
- alkyl
- pharmaceutically acceptable
- combinations
- therapy combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Polyesters Or Polycarbonates (AREA)
- Stored Programmes (AREA)
Abstract
combinações de terapia para malignidades hematológicas a presente invenção refere-se a métodos que se relacionam a uma nova estratégia terapêutica para o tratamento de malignidades hematológicas e doenças inflamatórias. em particular, o método compreende a administração de um composto de fórmula a, em que r é h, halo, ou c1-c6 alquila; r' é c1-c6 alquila; ou um sal farmaceticamente aceitável do mesmo; e opcionalmente um excipiente farmaceuticamente aceitável; e um ou mais agentes terapêuticos adicionais opcionalmente selecionados do grupo que consiste em bendamustina, rituximabe, e ofatumumabe.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161452034P | 2011-03-11 | 2011-03-11 | |
US201161493317P | 2011-06-03 | 2011-06-03 | |
PCT/US2012/028654 WO2012125510A1 (en) | 2011-03-11 | 2012-03-09 | Combination therapies for hematologic malignancies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112013022801A2 true BR112013022801A2 (pt) | 2019-09-24 |
Family
ID=45888489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112013022801A BR112013022801A2 (pt) | 2011-03-11 | 2012-03-09 | combinações de terapia para malignidades hematológicas |
Country Status (22)
Country | Link |
---|---|
US (3) | US20130064812A1 (pt) |
EP (2) | EP3187184A1 (pt) |
JP (2) | JP2014510729A (pt) |
KR (1) | KR20140022836A (pt) |
CN (1) | CN103826629A (pt) |
AP (1) | AP2013007158A0 (pt) |
AR (1) | AR085668A1 (pt) |
AU (2) | AU2012229266A1 (pt) |
BR (1) | BR112013022801A2 (pt) |
CA (1) | CA2829096A1 (pt) |
CL (1) | CL2013002552A1 (pt) |
CO (1) | CO6821936A2 (pt) |
CR (1) | CR20130517A (pt) |
EA (1) | EA201391263A1 (pt) |
EC (1) | ECSP13012964A (pt) |
MA (1) | MA35090B1 (pt) |
MX (1) | MX2013010439A (pt) |
PE (1) | PE20140405A1 (pt) |
SG (2) | SG193337A1 (pt) |
TW (1) | TW201242598A (pt) |
UY (1) | UY33947A (pt) |
WO (1) | WO2012125510A1 (pt) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2531142T3 (es) | 2005-10-17 | 2015-03-11 | Sloan Kettering Inst Cancer | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
ES2591029T3 (es) | 2006-04-10 | 2016-11-24 | Sloan Kettering Institute For Cancer Research | Péptidos WT-1 inmunogénicos y métodos para su uso |
US9259399B2 (en) | 2007-11-07 | 2016-02-16 | Cornell University | Targeting CDK4 and CDK6 in cancer therapy |
AU2009204487C1 (en) | 2008-01-04 | 2014-10-16 | Intellikine, Llc | Certain chemical entities, compositions and methods |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US9492449B2 (en) | 2008-11-13 | 2016-11-15 | Gilead Calistoga Llc | Therapies for hematologic malignancies |
EP3427739A1 (en) | 2008-11-13 | 2019-01-16 | Gilead Calistoga LLC | Therapies for hematologic malignancies |
BR112013017670B1 (pt) | 2011-01-10 | 2022-07-19 | Infinity Pharmaceuticals, Inc | Processos de preparação de isoquinolinonas e formas sólidas de isoquinolinonas |
JP6282598B2 (ja) | 2012-01-13 | 2018-02-21 | メモリアル スローン ケタリング キャンサー センター | 免疫原性wt1ペプチド及びその使用方法 |
EA035391B1 (ru) | 2012-11-08 | 2020-06-05 | Ризен Фармасьютикалз Са | Фармацевтические композиции, содержащие ингибитор pde4 и ингибитор pi3-дельта или двойной ингибитор pi3-дельта-гамма киназы |
US10815273B2 (en) | 2013-01-15 | 2020-10-27 | Memorial Sloan Kettering Cancer Center | Immunogenic WT-1 peptides and methods of use thereof |
CN116253788A (zh) | 2013-01-15 | 2023-06-13 | 纪念斯隆凯特林癌症中心 | 免疫原性wt-1肽和其使用方法 |
AU2014231816B2 (en) | 2013-03-12 | 2016-11-03 | Sumitomo Dainippon Pharma Co., Ltd. | Liquid aqueous composition |
CN103271897A (zh) * | 2013-06-04 | 2013-09-04 | 李春启 | 美司那在制备抗血管生成类药物中的应用 |
ES2535452B1 (es) * | 2013-08-02 | 2016-03-02 | Dalana3 S.L. | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas |
CA2931615A1 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
ES2873959T3 (es) | 2014-05-28 | 2021-11-04 | Piramal Entpr Ltd | Combinación farmacéutica que comprende un inhibidor de CDK y un inhibidor de tiorredoxina reductasa para el tratamiento del cáncer |
CN106470996B (zh) | 2014-07-04 | 2019-02-22 | 鲁平有限公司 | 作为pi3k抑制剂的喹嗪酮衍生物 |
CN105380956B (zh) * | 2015-11-04 | 2017-12-19 | 张陆军 | 一种治疗白血病的含艾德拉尼的药物组合物及应用 |
CA3028718A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2019108135A1 (en) * | 2017-11-30 | 2019-06-06 | Singapore Health Services Pte. Ltd. | A system and method for classifying cancer patients into appropriate cancer treatment groups and compounds for treating the patient |
TWI820146B (zh) * | 2018-06-15 | 2023-11-01 | 瑞典商阿斯特捷利康公司 | 嘌呤酮化合物及其在治療癌症中之用途 |
CN112569342A (zh) * | 2020-12-21 | 2021-03-30 | 中南大学 | 卡泊芬净和/或其可药用盐在制备抗肿瘤药物中的应用及抗肿瘤药物 |
CN116019798B (zh) * | 2022-07-20 | 2024-03-12 | 中南大学湘雅二医院 | 苯乙酰谷氨酰胺在制备预防和/或治疗阿霉素所致心脏毒性的药物中的应用 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1755609A1 (en) * | 2004-05-25 | 2007-02-28 | Icos Corporation | Methods for treating and/or preventing aberrant proliferation of hematopoietic cells |
EP3427739A1 (en) * | 2008-11-13 | 2019-01-16 | Gilead Calistoga LLC | Therapies for hematologic malignancies |
CA2759724A1 (en) * | 2009-04-20 | 2010-10-28 | Calistoga Pharmaceuticals, Inc. | Methods of treatment for solid tumors |
NZ736048A (en) * | 2010-06-03 | 2019-09-27 | Pharmacyclics Llc | The use of inhibitors of bruton’s tyrosine kinase (btk) |
-
2012
- 2012-03-09 CA CA2829096A patent/CA2829096A1/en not_active Abandoned
- 2012-03-09 EP EP17157706.7A patent/EP3187184A1/en not_active Withdrawn
- 2012-03-09 PE PE2013002034A patent/PE20140405A1/es not_active Application Discontinuation
- 2012-03-09 WO PCT/US2012/028654 patent/WO2012125510A1/en active Application Filing
- 2012-03-09 US US13/417,180 patent/US20130064812A1/en not_active Abandoned
- 2012-03-09 KR KR1020137026766A patent/KR20140022836A/ko not_active Application Discontinuation
- 2012-03-09 SG SG2013067129A patent/SG193337A1/en unknown
- 2012-03-09 AP AP2013007158A patent/AP2013007158A0/xx unknown
- 2012-03-09 EP EP12710838.9A patent/EP2683377A1/en not_active Withdrawn
- 2012-03-09 BR BR112013022801A patent/BR112013022801A2/pt not_active IP Right Cessation
- 2012-03-09 AU AU2012229266A patent/AU2012229266A1/en not_active Abandoned
- 2012-03-09 MX MX2013010439A patent/MX2013010439A/es not_active Application Discontinuation
- 2012-03-09 SG SG10201601909TA patent/SG10201601909TA/en unknown
- 2012-03-09 JP JP2013557934A patent/JP2014510729A/ja active Pending
- 2012-03-09 EA EA201391263A patent/EA201391263A1/ru unknown
- 2012-03-09 CN CN201280022394.XA patent/CN103826629A/zh active Pending
- 2012-03-12 AR ARP120100805A patent/AR085668A1/es unknown
- 2012-03-12 TW TW101108394A patent/TW201242598A/zh unknown
- 2012-03-12 UY UY0001033947A patent/UY33947A/es not_active Application Discontinuation
-
2013
- 2013-09-05 CL CL2013002552A patent/CL2013002552A1/es unknown
- 2013-09-30 CO CO13231986A patent/CO6821936A2/es not_active Application Discontinuation
- 2013-10-03 MA MA36292A patent/MA35090B1/fr unknown
- 2013-10-08 CR CR20130517A patent/CR20130517A/es unknown
- 2013-10-10 EC ECSP13012964 patent/ECSP13012964A/es unknown
-
2015
- 2015-01-16 US US14/599,287 patent/US20150196564A1/en not_active Abandoned
-
2016
- 2016-06-30 US US15/199,666 patent/US20170119771A1/en not_active Abandoned
- 2016-07-27 JP JP2016147201A patent/JP2016222700A/ja active Pending
- 2016-09-16 AU AU2016228272A patent/AU2016228272A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
AP2013007158A0 (en) | 2013-10-31 |
US20130064812A1 (en) | 2013-03-14 |
CO6821936A2 (es) | 2013-12-31 |
US20170119771A1 (en) | 2017-05-04 |
EP2683377A1 (en) | 2014-01-15 |
CA2829096A1 (en) | 2012-09-20 |
CN103826629A (zh) | 2014-05-28 |
US20150196564A1 (en) | 2015-07-16 |
EP3187184A1 (en) | 2017-07-05 |
WO2012125510A1 (en) | 2012-09-20 |
CR20130517A (es) | 2014-02-12 |
ECSP13012964A (es) | 2014-02-28 |
EA201391263A1 (ru) | 2014-06-30 |
MX2013010439A (es) | 2014-07-09 |
AU2012229266A1 (en) | 2013-05-02 |
MA35090B1 (fr) | 2014-05-02 |
PE20140405A1 (es) | 2014-03-22 |
AR085668A1 (es) | 2013-10-16 |
SG10201601909TA (en) | 2016-04-28 |
CL2013002552A1 (es) | 2014-09-05 |
SG193337A1 (en) | 2013-10-30 |
KR20140022836A (ko) | 2014-02-25 |
TW201242598A (en) | 2012-11-01 |
JP2014510729A (ja) | 2014-05-01 |
JP2016222700A (ja) | 2016-12-28 |
AU2016228272A1 (en) | 2016-10-06 |
UY33947A (es) | 2012-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112013022801A2 (pt) | combinações de terapia para malignidades hematológicas | |
MX349159B (es) | Derivados deuterados de ivacaftor. | |
BR112012009215A2 (pt) | "terapia combinada contra o cancer com compostos inibidores de hsp90" | |
EA201590371A1 (ru) | 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний | |
EA201391485A1 (ru) | Способы и композиции для лечения нейродегенеративных заболеваний | |
BR112015020600A2 (pt) | composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição | |
MY185103A (en) | Bezylamine derivatives as inhibitors of plasma kallikrein | |
EA201391486A1 (ru) | Способы и композиции для лечения болезни паркинсона | |
EA201101507A1 (ru) | Способы лечения солидных опухолей | |
BR112012020311A2 (pt) | "compostos, medicamento, método para inibir um ciclo de divisão celular, método para a profilaxia ou tratamento de câncer, e, uso do composto." | |
BR112012019762A2 (pt) | composto, composição, e, método para tratar uma doença. | |
CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
BR112013007343A2 (pt) | métodos para tratar eritema associado com rosácea e para tratar telangiectasia associada com rosácea, e, composição tópica | |
BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
BR112014006271A2 (pt) | composições farmacêuticas | |
MX2013012588A (es) | Inhibidores de cinasa. | |
EA201592254A1 (ru) | Производные пиразолопирролидин-4-она и их применение при лечении заболевания | |
BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
MX2013011532A (es) | Inhibidores de la proteina 90 de choque termico (hsp90). | |
IN2015MN00002A (pt) | ||
MY165902A (en) | Substituted pyridine derivatives as fabi inhibitors | |
BR112014023423A2 (pt) | terapia de combinação | |
AR086444A1 (es) | Composiciones farmaceuticas y metodos para tratar el cancer | |
BR112012031634A2 (pt) | composto, composição farmacêutica, uso de um composto, e método para tratar um paciente que sofre de ou susceptível a um distúrbio | |
BR112015030623A2 (pt) | agentes citotóxicos para o tratamento de câncer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2543 DE 01-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |